Connection

TOM COOPER to Mice

This is a "connection" page, showing publications TOM COOPER has written about Mice.
Connection Strength

1.199
  1. MBNL overexpression rescues cardiac phenotypes in a myotonic dystrophy type 1 heart mouse model. J Clin Invest. 2025 Feb 11; 135(7).
    View in: PubMed
    Score: 0.068
  2. Rescue of Scn5a mis-splicing does not improve the structural and functional heart defects of a DM1 heart mouse model. Hum Mol Genet. 2024 10 07; 33(20):1789-1799.
    View in: PubMed
    Score: 0.067
  3. The role of Limch1 alternative splicing in skeletal muscle function. Life Sci Alliance. 2023 06; 6(6).
    View in: PubMed
    Score: 0.060
  4. Alternative splicing mediates the compensatory upregulation of MBNL2 upon MBNL1 loss-of-function. Nucleic Acids Res. 2023 02 22; 51(3):1245-1259.
    View in: PubMed
    Score: 0.060
  5. Increased nuclear but not cytoplasmic activities of CELF1 protein leads to muscle wasting. Hum Mol Genet. 2020 06 27; 29(10):1729-1744.
    View in: PubMed
    Score: 0.050
  6. Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1. Muscle Nerve. 2019 12; 60(6):779-789.
    View in: PubMed
    Score: 0.047
  7. CRISPR -Mediated Expression of the Fetal Scn5a Isoform in Adult Mice Causes Conduction Defects and Arrhythmias. J Am Heart Assoc. 2018 10 02; 7(19):e010393.
    View in: PubMed
    Score: 0.044
  8. Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet. 2018 08 15; 27(16):2789-2804.
    View in: PubMed
    Score: 0.044
  9. Extensive alternative splicing transitions during postnatal skeletal muscle development are required for calcium handling functions. Elife. 2017 08 11; 6.
    View in: PubMed
    Score: 0.041
  10. Alternative Splicing of Four Trafficking Genes Regulates Myofiber Structure and Skeletal Muscle Physiology. Cell Rep. 2016 11 15; 17(8):1923-1933.
    View in: PubMed
    Score: 0.039
  11. Neonatal cardiac dysfunction and transcriptome changes caused by the absence of Celf1. Sci Rep. 2016 10 19; 6:35550.
    View in: PubMed
    Score: 0.038
  12. The RNA-binding protein Rbfox1 regulates splicing required for skeletal muscle structure and function. Hum Mol Genet. 2015 Apr 15; 24(8):2360-74.
    View in: PubMed
    Score: 0.034
  13. Rbfox2-coordinated alternative splicing of Mef2d and Rock2 controls myoblast fusion during myogenesis. Mol Cell. 2014 Aug 21; 55(4):592-603.
    View in: PubMed
    Score: 0.033
  14. Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. Nat Commun. 2014 Apr 22; 5:3603.
    View in: PubMed
    Score: 0.032
  15. The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression. Cell Rep. 2014 Jan 30; 6(2):336-45.
    View in: PubMed
    Score: 0.032
  16. Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy. Proc Natl Acad Sci U S A. 2013 Aug 13; 110(33):13570-5.
    View in: PubMed
    Score: 0.031
  17. RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci U S A. 2012 Mar 13; 109(11):4221-6.
    View in: PubMed
    Score: 0.028
  18. Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol. 2011 Apr; 69(4):681-90.
    View in: PubMed
    Score: 0.026
  19. Global regulation of alternative splicing during myogenic differentiation. Nucleic Acids Res. 2010 Nov; 38(21):7651-64.
    View in: PubMed
    Score: 0.025
  20. CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Genet. 2010 Sep 15; 19(18):3614-22.
    View in: PubMed
    Score: 0.025
  21. MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development. Genes Dev. 2010 Apr 01; 24(7):653-8.
    View in: PubMed
    Score: 0.024
  22. Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet. 2010 Mar 15; 19(6):1066-75.
    View in: PubMed
    Score: 0.024
  23. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest. 2009 Dec; 119(12):3797-806.
    View in: PubMed
    Score: 0.024
  24. Chemical reversal of the RNA gain of function in myotonic dystrophy. Proc Natl Acad Sci U S A. 2009 Nov 03; 106(44):18433-4.
    View in: PubMed
    Score: 0.024
  25. Molecular biology. Neutralizing toxic RNA. Science. 2009 Jul 17; 325(5938):272-3.
    View in: PubMed
    Score: 0.023
  26. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20333-8.
    View in: PubMed
    Score: 0.022
  27. Expanded CTG repeats within the DMPK 3' UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci U S A. 2008 Feb 19; 105(7):2646-51.
    View in: PubMed
    Score: 0.021
  28. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell. 2007 Oct 12; 28(1):68-78.
    View in: PubMed
    Score: 0.021
  29. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy. J Clin Invest. 2007 Oct; 117(10):2802-11.
    View in: PubMed
    Score: 0.021
  30. Micromanaging alternative splicing during muscle differentiation. Dev Cell. 2007 Feb; 12(2):171-2.
    View in: PubMed
    Score: 0.020
  31. A bichromatic fluorescent reporter for cell-based screens of alternative splicing. Nucleic Acids Res. 2006; 34(22):e148.
    View in: PubMed
    Score: 0.019
  32. A reversal of misfortune for myotonic dystrophy? N Engl J Med. 2006 Oct 26; 355(17):1825-7.
    View in: PubMed
    Score: 0.019
  33. Minigene reporter for identification and analysis of cis elements and trans factors affecting pre-mRNA splicing. Biotechniques. 2006 Aug; 41(2):177-81.
    View in: PubMed
    Score: 0.019
  34. Dynamic balance between activation and repression regulates pre-mRNA alternative splicing during heart development. Dev Dyn. 2005 Jul; 233(3):783-93.
    View in: PubMed
    Score: 0.018
  35. Cardiac tissue-specific repression of CELF activity disrupts alternative splicing and causes cardiomyopathy. Mol Cell Biol. 2005 Jul; 25(14):6267-78.
    View in: PubMed
    Score: 0.018
  36. Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet. 2005 Jun 01; 14(11):1539-47.
    View in: PubMed
    Score: 0.017
  37. Modulation of alternative splicing of trafficking genes by genome editing reveals functional consequences in muscle biology. Int J Biochem Cell Biol. 2018 12; 105:134-143.
    View in: PubMed
    Score: 0.011
  38. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep 17; 525(7569):384-8.
    View in: PubMed
    Score: 0.009
  39. Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins. Genome Res. 2015 Jun; 25(6):858-71.
    View in: PubMed
    Score: 0.009
  40. Pumilio1 haploinsufficiency leads to SCA1-like neurodegeneration by increasing wild-type Ataxin1 levels. Cell. 2015 Mar 12; 160(6):1087-98.
    View in: PubMed
    Score: 0.009
  41. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc Natl Acad Sci U S A. 2011 Mar 01; 108(9):3665-70.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.